Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2008-05-11 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT Presents Encapsulation Technology at Conference 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated May 12, 2008, from Living Cell Technologies Ltd. It discusses the company's presentation of its encapsulation technology at an international conference. The content focuses on the technology, clinical trial status, and the invitation to present at the conference. There are no financial statements, regulatory filings, voting results, or management changes reported. The document is a press release-style announcement about a presentation event rather than a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or company news that does not fit other specific categories, which corresponds to Regulatory Filings (RNS). The document length is 5749 characters, which is sufficient for a full report but the content is clearly an announcement, not a report itself.
2008-05-11 English
LCT Prepares to List on the International OTCQX 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated May 8, 2008, regarding Living Cell Technologies Limited's application to list its American Depository Receipt (ADR) program on the International OTCQX market. The content focuses on the listing application and the expected benefits of this listing for the company and its investors. There are no financial statements, detailed financial performance data, or management discussion of results. The document is relatively short (5582 characters) and serves as a disclosure or announcement rather than a full financial report or presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a regulatory certification or officer attestation. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a listing application and does not fit more specific categories.
2008-05-07 English
LCT Diabetes Treatment to feature on Channel Ten News 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Ltd dated May 8, 2008. It discusses a news feature on Channel Ten about the company's diabetes treatment product, DiabeCell, including clinical trial updates and patient outcomes. The text includes forward-looking statements and contact information for investor and media relations. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is primarily an announcement about media coverage and clinical trial progress rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or governance-related document. Given the content and length (7052 characters), it is best classified as a Regulatory Filing (RNS) because it is a general company announcement that does not fit other specific categories.
2008-05-07 English
Appendix 4C - quarterly 7 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Living Cell Technologies Enhanced Cash Position - Appendix 4C Quarterly Report' and includes detailed financial data such as cash flows related to operating, investing, and financing activities for the quarter ended March 31, 2008. It contains actual financial statements and analysis, including reconciliation of cash, payments to directors, and compliance statements. The Appendix 4C is a recognized quarterly report format for entities admitted on the basis of commitments, commonly used in Australian stock exchange filings. The document is over 12,000 characters, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2008
2008-04-29 English
Change in substantial holding from AXA 8 pages ?Kb
Regulatory Filings
2008-04-02 English
LCT Showcases Proprietary Nanobiocapsules at NZBio 2008 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Ltd dated April 2, 2008. It discusses a presentation at a conference (NZBio 2008) showcasing proprietary nanobiocapsules technology and reports on preliminary clinical trial data. The content is focused on scientific and technological updates rather than financial results, regulatory filings, or shareholder matters. There is no indication of financial statements, audit information, management changes, voting results, or other regulatory filings. The document is a press release-style announcement about a scientific presentation and clinical trial progress, which fits best under a general regulatory announcement category rather than a specific financial or governance report. Given the nature and content, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other categories.
2008-04-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.